Shandong Xinhua Pharmaceutical Company Limited (HKG: 0719, SHE: 000756) announced that it has received a Drug Registration Certificate from China’s National Medical Products Administration (NMPA) for Sacubitril/Valsartan Sodium Tablets (sacubitril 24 mg / valsartan 26 mg, 50 mg strength), approved as a Class 4 chemical drug for the treatment of adult patients with chronic heart failure with reduced ejection fraction (HFrEF). The product is listed in the 2025 National Reimbursement Drug List (NRDL) as a Category B product, and total sales of sacubitril/valsartan sodium tablets in China’s public medical institutions reached approximately RMB 7.8 billion (~US$1.1 billion) in 2025.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Drug registration (domestic production) |
| Product | Sacubitril/Valsartan Sodium Tablets (sacubitril 24 mg / valsartan 26 mg, 50 mg) |
| Registration Classification | Class 4 chemical drug (generic equivalent) |
| Drug Category | Prescription drug |
| Case Number | CYHS2501636 |
| Drug Approval Number | National Medicine Zhunzi H20266108 |
| Certificate Number | 2026S03596 |
| CDE Submission | April 2025 |
| Approval Date | October 2026 |
| Review Timeline | ~18 months from acceptance to approval |
Drug Profile & Mechanism of Action
- Molecule: Sacubitril/valsartan (sacubitril + valsartan) — a first‑in‑class angiotensin receptor‑neprilysin inhibitor (ARNI) originally developed by Novartis (brand name: Entresto® / 诺欣妥®).
- Approved Indication: Adult patients with chronic heart failure with reduced ejection fraction (HFrEF) — specifically NYHA class II–IV, LVEF ≤40% — to reduce the risk of cardiovascular death and heart failure hospitalization.
- Mechanism (Dual Action):
- Sacubitril: A prodrug that inhibits neprilysin, a neutral endopeptidase that degrades natriuretic peptides (ANP, BNP). By inhibiting neprilysin, sacubitril augments the natriuretic peptide system, promoting vasodilation, natriuresis, and anti‑fibrotic/anti‑hypertrophic effects.
- Valsartan: An angiotensin II receptor blocker (ARB) that blocks the renin‑angiotensin‑aldosterone system (RAAS), reducing vasoconstriction, sodium retention, and cardiac remodeling.
- Clinical Positioning: Sacubitril/valsartan replaces ACE inhibitors (ACEI) or ARBs in guideline‑directed medical therapy (GDMT) for HFrEF, in combination with beta‑blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — the current “four pillars” of heart failure treatment.
- Guideline Status: Recommended as first‑line therapy (Class I, Level A evidence) in all major international and Chinese heart failure guidelines (ESC, AHA/ACC/HFSA, Chinese Society of Cardiology).
Market Landscape
| Parameter | Detail |
|---|---|
| 2025 China Public Hospital Sales | ~RMB 7.8 billion (~US$1.1 billion) |
| NRDL Status | Category B (2025 National Reimbursement Drug List) |
| Originator Product | Entresto® / 诺欣妥® (Novartis) |
| Market Dynamics | Originator patent expiry enabling generic entry |
- China Heart Failure Epidemiology: China has an estimated ~13.7 million heart failure patients, with HFrEF representing approximately ~40–50% of the total HF population. The growing prevalence of hypertension, diabetes, and ischemic heart disease — coupled with population aging — continues to drive expansion of the HFrEF treatment market.
- RMB 7.8 Billion Market: The 2025 sales figure of RMB 7.8 billion in public medical institutions alone underscores sacubitril/valsartan’s position as one of China’s highest‑value cardiovascular drugs, reflecting both broad clinical adoption and the chronic, long‑duration nature of heart failure therapy.
Strategic Rationale for Xinhua Pharmaceutical
- Anti‑Hypertension Portfolio Enrichment: The approval adds a high‑value, guideline‑recommended cardiovascular product to Xinhua Pharmaceutical’s existing anti‑hypertension product series, strengthening the company’s competitive position in one of China’s largest therapeutic categories.
- NRDL Category B Advantage: The product’s inclusion in the 2025 NRDL as a Category B product means that generic entrants like Xinhua can immediately access the reimbursement system upon approval, avoiding the lengthy and competitive NRDL negotiation process required for new drugs. This accelerates market access and hospital formulary listing.
- Generic Entry Timing: As one of the early generic entrants in the sacubitril/valsartan market following originator patent expiry, Xinhua is positioned to capture share from the originator through pricing advantages while benefiting from the established clinical acceptance and prescribing habits built by Novartis’s Entresto® commercialization efforts.
- VBP Eligibility: As a Class 4 chemical drug, the product will be eligible for future national volume‑based procurement (VBP) rounds — China’s primary mechanism for generic drug market access. Early generic entrants typically benefit from favorable VBP pricing dynamics before the market becomes crowded.
Market Impact & Outlook
- Generic ARNI Market Emergence: The approval of Xinhua’s generic sacubitril/valsartan signals the beginning of generic competition in one of China’s most valuable cardiovascular drug markets. Generic entry is expected to expand patient access through lower pricing while compressing per‑unit margins — a dynamic that favors manufacturers with cost‑efficient production and established hospital channel relationships.
- Reimbursement Tailwind: With the product already in the NRDL (Category B), Xinhua faces no reimbursement barrier to market entry — a significant advantage in China’s public hospital‑dominated pharmaceutical market, where NRDL listing is a prerequisite for volume prescribing.
- VBP Risk and Opportunity: Future inclusion in national VBP rounds will likely drive significant price reductions (historically 40–60%+ for generic cardiovascular drugs) but will also guarantee volume across participating hospitals. Manufacturers with the lowest cost structures and strongest manufacturing capacity will be best positioned.
- Competitive Intensity: As the originator’s patent protection expires, multiple generic manufacturers are expected to pursue sacubitril/valsartan registrations in China. Xinhua’s early approval provides a first‑mover advantage in establishing hospital formulary listings and physician prescribing habits before the generic market becomes saturated.
- HFrEF Treatment Expansion: China’s HFrEF treatment market is expected to continue growing as guideline adherence improves, diagnosis rates increase, and SGLT2 inhibitors (the fourth pillar) further validate the multi‑drug GDMT approach — driving incremental demand for sacubitril/valsartan as the foundational RAAS/neprilysin component.
- Manufacturing Scale: Xinhua Pharmaceutical’s ability to achieve cost‑competitive manufacturing of sacubitril/valsartan — a co‑crystal formulation requiring specialized API synthesis and formulation technology — will be a critical determinant of long‑term commercial success in an increasingly price‑competitive generic market.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercial potential of sacubitril/valsartan sodium tablets, market access dynamics, VBP participation, and competitive positioning in China’s heart failure therapeutic market. Actual results may differ materially due to risks including VBP pricing outcomes, competitive dynamics from other generic entrants and the originator product, hospital formulary listing timelines, manufacturing scale‑up, reimbursement policy changes, bidding and procurement process uncertainties, and changes in domestic pharmaceutical industry policies. Investors are advised to exercise caution.-Fineline Info & Tech
